Response Assessment Challenges in Clinical Trials of Gliomas

摘要: Accurate, reproducible criteria for determining tumor response and progression after therapy are critical optimal patient care effective evaluation of novel therapeutic agents. Currently, the most widely used treatment in gliomas is based on two-dimensional measurements using neuroimaging studies (Macdonald criteria). In recent years, limitation these criteria, which only address contrast-enhancing component tumor, have become increasingly apparent. This review discusses challenges that emerged assessing patients with approaches being introduced to them.